Adverse drug reactions in hospitalized paediatric patients in a tertiary care center in Kerala, India
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20183937Keywords:
Children, Drug safety, Inpatient, India, Kerala, PharmacovigilanceAbstract
Background: Drug safety information about children is scarcely available. This study aims to describe the ADRs in hospitalized paediatric patients under 12 years of age in paediatrics wards of DM WIMS Hospital, Wayanad, Kerala, a tertiary care center in southern part of India.
Methods: A retrospective study based on data collected as per the ongoing pharmacovigilance program of India (PvPI) was conducted for twelve months period in order to study the ADRs in hospitalized paediatric patients under 12 years of age with at least one medication prescribed. The study was conducted in paediatrics wards of DM WIMS Hospital, Wayanad. WHO-UMC scale and Naranjo´s Algorithm was used to evaluate causality, the modified Hartwig and Siegel assessment scale was used to establish severity and the Schumock and Thornton criteria was used to determine preventability.
Results: Forty-two children (42) who experienced 55 ADRs were included in the study. The frequency was higher in children under 1 year of age (47.62%). Emergence of ADRs was higher in male patients (59.52%), in those used three or more medicines together (71.43%) and in those with systemic antibiotics (58.18%).
Conclusions: Being the first study from Kerala in paediatric patients, it is an important contribution to drug safety profile in children from this region of India. ADRs frequency and other descriptive characteristics are provided for the enrolled children under 12 years of age. ADRs are an additional burden of morbidity and risk, particularly in those who used several medicines, including antibiotics.
References
Smyth RMD, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R. Adverse drug reactions in children -a systematic review. PLoS One.2012;7(3):e24061.
The WHO Programme for International Drug Monitoring. Available at: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/National_PV_Centres_Map/en/. Accessed on 24 Jul 2018.
Kalaiselvan V, Thota P, Singh GN. Pharmacovigilance Programme of India: Recent developments and future perspectives. Ind J of Pharmacol. 2016;48(6):624-28.
Thota P, Thota A, Medhi B, Sidhu S, Kumar P, Selvan VK, Singh GN. Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India. Perspectives Clin Res. 2018 Jan;9(1):51.
Anuradha HV, Shivaswamy KN, Rachana PR. Evaluation of cutaneous adverse drug reactions due to antimicrobial agents: a prospective study. IOSR J of Dent and Medi Sci. 2015;4(11):19-22.
Baek HJ, Cho YS, Kim KS, Lee J, Kang HR, Suh DI. Multidisciplinary approach to improve spontaneous ADR reporting in the pediatric outpatient setting: a single-institute experience in Korea. Springer Plus. 2016 Dec 1;5(1):1435.
Salas RD, Díaz-Agudelo D, Burgos-Flórez FJ, Vaca C, Serrano-Meriño DV. Adverse drug reactions in hospitalized Colombian children. Colombia Med. 2016 Sep;47(3):142-7.
Napoleone. Children and ADRs (Adverse Drug Reactions). Italian Journal of Pediatrics. 2010;36:4 Available at: http://www.ijponline.net/content/36/1/4. Accessed on 24 Jul 2018.
Lieber NS, Ribeiro E. Adverse drug reactions leading children to the emergency department. Rev Bras Epidemiol. 2012 Jun;15(2):265-74.
Divyalasya TVS, Vasundara KHT, Yashoda, Pundarikaksha HP, Kudagi BL, Ramamohan P. Adverse drug reactions in paediatric patients in a tertiary care hospital in India: a prospective observational single centre study. Int J Basic Clin Pharmacol. 2016 Oct;5(5):2130-37.
Suspected Adverse Drug Reaction Reporting Form. Available at:
http://www.cdsco.nic.in/writereaddata/ADR%20form%20PvPI.pdf. Accessed on 24 Jul 2018.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruis I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther.1981;30:239-45.
The use of the WHO–UMC system for standardized case causality assessment. Available at: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf. Accessed on 24 Jul 2018.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Health System Pharmacy. 1992 Sep 1;49(9):2229-32.
Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hospital Pharmacy. 1992 Jun;27(6):538.
Kazeem AO, Henry C, Olisamedua FN, Idowu OS, Iyabo O. Incidence and cost estimate of treating pediatric adverse drug reactions in Lagos, Nigeria. Sao Paulo Med J. 2011;129(3):153-64.
Gholami K, Parsa S, Shalviri G, Sharifzadeh M, Assasi N. Anti‐infectives‐induced adverse drug reactions in hospitalized patients. Pharmacoepidemiol Drug Safety. 2005 Jul;14(7):501-6.
Wu WK, Pantaleo N. Evaluation of outpatient adverse drug reactions leading to hospitalization. Am J Health Syst Pharm. 2003;60(3):253-59.
Rajakannan T, Mallayasamy S, Guddattu V, Kamath A, Vilakkthala R, Rao PG, et al. Cost of adverse drug reactions in a South Indian tertiary care teaching hospital. J Clin Pharmacol. 2012 Apr;52(4):559-65.
Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol. 2007 Dec;7(1):8.
Hopf YM, Bond C, Francis J, Haughney J, Helms PJ. ‘The more you link, the more you risk’-a focus group study exploring views about data linkage for pharmacovigilance. Br J Clin Pharmacol. 2014 Nov;78(5):1143-50.
Kaushal R, Bates DW, Landrigan C, McKenna KJ, Clapp MD, Federico F, Goldmann DA, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001 Apr 25;285(16):2114-20.
Priyadharsini R, Surendiran A, Adithan C, Sreenivasan S, Sahoo FK. A study of adverse drug reactions in pediatric patients. J Pharmacol Pharmacotherapeut. 2011 Oct;2(4):277.
Reena V, Jyotsna V, Nitin V, Parag S, Niket R. A study of adverse drug reactions in paediatric age group with assessment of causality, severity and preventabilty in a tertiary care hospital. J Dent Med Sci. 2014;13(5):42-8.
Digra KK, Pandita A, Saini GS, Bharti R. Pattern of adverse drug reactions in children attending the department of pediatrics in a tertiary care center: a prospective observational study. Clin Med Insights: Pediatrics. 2015 Jan;9:CMPed-S29493.
Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out‐patients: a systematic review and meta‐analysis of prospective studies. Br J Clin Pharmacol. 2001 Jul;52(1):77-83.
Mortazavi SS, Shati M, Keshtkar A, Malakouti SK, Bazargan M, Assari S. Defining polypharmacy in the elderly: a systematic review protocol. BMJ Open. 2016 Mar 1;6(3):e010989.
Rashed AN, Wong IC, Cranswick N, Tomlin S, Rascher W, Neubert A. Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study. Eur J Clin Pharmacol. 2012 May 1;68(5):801-10.
Titchen T, Cranswick N, Beggs S. Adverse drug reactions to nonsteroidal anti‐inflammatory drugs, COX‐2 inhibitors and paracetamol in a paediatric hospital. Br J Clin Pharmacol. 2005 Jun;59(6):718-23.
Thompson G, Barker CI, Folgori L, Bielicki JA, Bradley JS, Lutsar I, et al. Global shortage of neonatal and paediatric antibiotic trials: rapid review. BMJ Open. 2017 Oct 1;7(10):e016293.
Shree Lakshmi Devi S, Basalingappa S, Abilash SC. A study of adverse drug reactions among elderly patients in a tertiary care hospital. Int J Basic Clin Pharmacol. 2017;Aug;6(8):1894-99.
Allegaert K, Anker JN. Adverse drug reactions in neonates and infants: a population‐tailored approach is needed. Br J Clin Pharmacol. 2015 Oct 1;80(4):788-95.
Crom WR. Pharmacokinetics in the child. Environ Health Perspect. 1994;102(Suppl 11):111-17.
Arimone Y, Miremont‐Salamé G, Haramburu F, Molimard M, Moore N, Fourrier‐Réglat A, et al. Inter‐expert agreement of seven criteria in causality assessment of adverse drug reactions. Br J Clin Pharmacol. 2007 Oct 1;64(4):482-8.
Belhekar MN, Taur SR, Munshi RP. A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions. Indian J Pharmacol. 2014 Jan;46(1):117.
Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R, Segal R. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Sys Pharma. 2003 Sep 1;60(17):1750-9.
